Secukinumab: A Review in Moderate to Severe Plaque Psoriasis

@article{Garnockjones2015SecukinumabAR,
  title={Secukinumab: A Review in Moderate to Severe Plaque Psoriasis},
  author={K. P. Garnock-jones},
  journal={American Journal of Clinical Dermatology},
  year={2015},
  volume={16},
  pages={323-330}
}
  • K. P. Garnock-jones
  • Published 2015
  • Medicine
  • American Journal of Clinical Dermatology
  • Secukinumab (Cosentyx™) is a fully human monoclonal immunoglobulin G1κ antibody targeting human interleukin-17A, an important cytokine in the pathogenesis of psoriasis. Secukinumab, as well as being first in its drug class, is the first biologic treatment to be approved in the EU for the first-line systemic treatment of moderate to severe plaque psoriasis. This article reviews the pharmacologic properties of secukinumab and its clinical efficacy and tolerability in adult patients with moderate… CONTINUE READING
    32 Citations

    Figures, Tables, and Topics from this paper

    Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
    • 9
    • PDF
    Secukinumab: A Review in Psoriatic Arthritis
    • 16
    Secukinumab for the treatment of residual psoriasis: a case series
    • P. Malagoli
    • Medicine
    • The Journal of dermatological treatment
    • 2018
    • 1
    Secukinumab: A Review in Ankylosing Spondylitis
    • 21
    Scalp psoriasis: report of efficient treatment with secukinumab
    Secukinumab: A Review in Ankylosing Spondylitis
    • 5
    • PDF

    References

    SHOWING 1-10 OF 42 REFERENCES
    Secukinumab in plaque psoriasis--results of two phase 3 trials.
    • 1,212
    • Highly Influential
    • PDF
    Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    • 347
    • Highly Influential
    • PDF
    Secukinumab: First Global Approval
    • 71
    Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
    • 26
    • PDF
    European S3‐Guidelines on the systemic treatment of psoriasis vulgaris
    • 614
    • Highly Influential
    • PDF